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1. Introduction
In 2009, UNAIDS reported ~ 33.4 million people were infected with HIV globally.
For the same year, there were 2.2. million new HIV infections and 2 million HIV-
related deaths reported [1]. Developing countries, in particular, face a high burden of
HIV disease that manifests as severely compromised immunity and increased sus-
ceptibility to other infectious opportunistic diseases [2]. In this regard, elevated prev-
alence of tuberculosis (TB)--HIV co-infection has been demonstrated, for example
in South Africa, where up to 73% of patients diagnosed with active TB have been
shown to be HIV-positive [2]. HIV-positive patients show a 20- to 37-fold greater
risk of developing active TB than those who are HIV-negative [3]. Despite the
high TB burden in HIV infected people, standard symptom, microbiological and
radiologic screenings for TB are not routinely undertaken when TB is not the pre-
senting clinical condition, resulting in unnecessary morbidity and mortality in HIV
infected people [3]. In addition to being the most common co-morbidity, TB is also
the leading cause of death in those who are HIV infected [2]. The emerging multi-
drug resistant (MDR) and extensively drug resistant (XDR) forms of the TB--HIV
epidemics further complicate this situation [4].
Strategies and policies to effectively integrate the management of both diseases
are, therefore, critical, but have been limited by the lack of rigorous and consistent
evidence [5]. Rapid scale-up of HIV treatment in resource-constrained settings has
been made possible with global solidarity and notable donor funding through the
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President’s Emergency Plan for AIDS Relief (PEPfAR) and
the Global Fund to Fight AIDS, TB and Malaria (GFATM)
that have enhanced infrastructure, skilled human resources
and increased antiretroviral treatment (ART) access.
Barriers to integrated HIV and TB treatment have tradi-
tionally included a lack of rigorous empiric evidence on how
to safely manage co-infected patients [6]. The obstacles include
traditional separation of facilities to treat HIV and TB; the
lack of clear clinical guidance on immune reconstitution
inflammatory syndrome (IRIS) detection and management;
fear of potential drug--drug interactions; additive drug toxic-
ities and tolerability issues and the adherence challenges asso-
ciated with high pill burdens [7,8]. The ambivalence regarding
‘during TB’ or ‘post-TB’ ART initiation based on arbitrary
CD4 cell count cutoffs has also been a major factor impeding
co-management of the two diseases at a programmatic
level [9,10]. Although some observational studies have shown
that mortality was reduced when TB and HIV therapies are
combined [9,11-13], the strength of evidence for integration
has been substantially advanced with the completion of the
first randomized clinical trial [14].
The purpose of this review is to examine the complex
drug--drug interactions that have been a known barrier to
integrating antiretroviral (ARV) and TB treatment and to
provide recommendations on the clinical management of
co-infected patients. Available data on new classes of ARVs
and drug--drug interactions with first-line TB drugs are also
briefly discussed. The goals for combined treatment of HIV
and TB are to reduce morbidity and mortality associated
with both diseases. Attaining TB cure within 6 -- 9 months
of initiating anti-TB treatment and optimal HIV viral load
suppression to undetectable levels by 6 months is desirable.
These goals need to be attained with minimal drug-related
adverse events, without compromising the TB treatment or
the longevity of the first-line ART regimen. Exposure to
sub-therapeutic drug concentrations which may poten-
tially induce resistance mutations in both organisms must
be avoided.
2. Review: co-administration of ARV drugs
with first-line TB treatment
In 2005, Di Perri et al. reviewed the drug--drug inter-
actions between anti-TB and ARV drugs in this journal [6].
This review aims to update the earlier review and include
limited data on newer classes of ARVs. The potential for
additive toxicities as well as updates on IRIS incidence and
management and mortality data during early co-treatment
are highlighted.
2.1 Pharmacological basis for potential ART--first-line
TB drug interactions
Alterations in drug disposition may occur at various stages
after oral administration (Figure 1) as a result of interacting
drugs or disease influences [15].
Interactions at the level of absorption and hepatic
elimination are of most significance in relation to the
co-administration of TB and ARV drugs. Drugs that alter
the pH of the gastrointestinal tract may alter absorption of
other drugs. Variable malabsorption of TB drugs by patients
with advanced HIV disease has also been reported in several
studies with a potentially detrimental impact on TB treatment
outcomes [16-19]. TB drug malabsorption is thought to be
more likely when concurrent gastrointestinal infection or
diarrhea or advanced immunodeficiency with or without
diarrhea is present [17-19].
Gastrointestinal and hepatic metabolism of TB and ARV
drugs have been extensively studied [20-22]. The proposed
mechanisms of the TB--ARV drug interactions are related
mainly to substrate activity, inhibition or induction of the
hepatic CYP monooxygenase enzyme system (Figure 2) [21].
The *CYP450 isoforms that are most commonly associated
with TB--HIV drug interactions [21,23,24] are listed
in Figure 2. Modulation of the P-glycoprotein cellular trans-
port system in the intestinal mucosa can increase the efflux
of drugs from cells and prevent absorption of certain drugs [21].
Rifampicin (RIF) is a known inducer and several protease
inhibitors (PIs) are either substrates for or inhibitors of this
transport system [21,25]. The resultant effect following hepatic-
or transporter-mediated pharmacokinetic interactions may
impact treatment outcome in two ways depending on the
potency of the effect: sub-therapeutic concentrations may
result in treatment failure and higher concentrations may be
associated with treatment-limiting toxicity [15,21].
The main pharmacokinetic drug--drug interactions expected
between TB treatment and ART are related to hepatic elimina-
tion, involving the rifamycin class of TB antimicrobials (RIF,
rifabutin (RFB) and rifapentine (RFP)), the non-nucleoside
Article highlights.
. An overall understanding of the current state of the
inter-connected tuberculosis (TB)--HIV epidemics and the
potential barriers to treatment integration.
. The pharmacological basis for antiretroviral (ARV)--TB
drug interactions and the influence of CYP
isoenzyme effects.
. A summary of the effect of combining rifamycins and all
available non-nucleoside reverse transcriptase inhibitors.
. A summary of the effect of combining rifamycins and all
available protease inhibitors.
. Updated dose modifications are necessary when
combining ARVs and TB drugs.
. Updated data on additive and overlapping toxicities.
. Centrality of adherence to treatment.
. Predictors and management of immune reconstitution
inflammatory syndrome.
. Latest data on survival benefits when combing TB and
ARV treatment agents.
. An expert opinion on future research priorities.
This box summarizes key points contained in the article.
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reverse transcriptase inhibitors (NNRTIs) and the PIs [9,21].
Other first-line TB drugs such as isoniazid, ethambutol and
pyrazinamide, although metabolized hepatically, are not
reported to significantly influence the CYP enzyme system in
humans [26]. There is also potential for rifamycin interaction
with newer ART classes, such as the CCR5--receptor antago-
nists and integrase inhibitors, based on current knowledge of
metabolic pathways. There are no significant established drug
interactions with the older nucleoside reverse transcriptase
inhibitors (NRTIs), with the possible exception of zidovudine
(ZDV), or the entry inhibitor class agent, enfuvirtide [27].
2.1.1 Rifamycins as the preferred backbone of
first-line TB treatment
Rifamycin-based TB regimens have been used successfully to
manage TB in HIV positive patients and have been found to
be most effective if administered throughout TB treatment [28].
High relapse rates have been evident if rifamycins were used
only in the first 2 months of treatment [29] and a minimum of
6 months of rifamycin treatment is required to effect a
cure [29,30]. Some have advocated an even longer duration of
8 ormoremonths when treatingHIV co-infected patients [31,32].
Non-rifamycin-based regimens are considered less potent, as
Absorption 
Drugs/disease that alter pH or mucosal
absorptive capacity may affect absorption
Gastro-intestinal metabolism or
transport
Inhibition or induction of enzymes or
modulation of transporter proteins
Hepatic metabolism or transport 
Inhibition or induction of enzymes or
modulation of transporter proteins 
Renal elimination 
Inhibition of transporter proteins



































Figure 2. Possible metabolic drug interactions and the CYP system.
*Cytochrome P450 monooxygenase (CYP) system isoenzymes most commonly associated with TB-HIV drug interactions.
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they increase the TB treatment duration to 18 -- 24 months
and are associated with higher toxicity and relapse rates [23,29].
RIF is the most widely available and most commonly used
of the rifamycins [31]. RFB has similar efficacy to RIF but is
more expensive, neither widely available in high TB preva-
lence countries nor in fixed dose combinations and its use is
complicated by the fact that as a substrate for CYP3A4,
RFB is subject to dose modification when co-administered
with ARVs [27,33]. RFP has been shown to be less effective in
effecting TB cure in those with advanced disease and is not
currently advocated for first-line TB treatment in HIV-
positive cases [34]. There were concerns with the intermittent
dosing strategies used to previously test RFP as no accompa-
nying TB drug has a similar long half-life, which probably
led to the high failure rates observed [35]. Studies are currently
underway testing daily dosing of RFP [36,37]. However, due to
these uncertainties and lack of data, RFP is excluded from
further discussion in this review.
Standard treatment for uncomplicated pulmonary TB, par-
ticularly in developing countries, comprises of a minimum of
2 month intensive phase treatment combination consisting of
RIF, isoniazid, pyrazinamide and ethambutol and a minimum
4 month continuation treatment combination of RIF and
isoniazid, dosed 5 -- 7 days a week. Streptomycin (aminogly-
coside) is added for re-treatment cases that are still susceptible
to first-line treatment [31].
Drug interactions with the rifamycins RIF or RFB, therefore,
need to be anticipated and managed for the entire duration of
TB treatment. The relative extent of CYP3A induction is
RIF > RFP > RFB [38]. RIF is a potent inducer of CYP3A and
a strong inducer of CYP2B6. RIF’s concentration is not influ-
enced by CYP3A induction, whereas RFB toxicity is influenced
by its dose and the presence of CYP3A inhibitors [38].
2.2 Drug interactions between RIF/RFB and
NNRTI class
NNRTIs are widely prescribed as the backbone of first-
line ART, particularly in developing countries. Both efavirenz
(EFV) and nevirapine (NVP) are metabolized by the CYP
enzyme system. The CYP2B6 isoform is primarily responsible
for EFV metabolism and the CY3A4 isoform is primarily
responsible for NVP metabolism and to a less significant
extent for EFV metabolism [24]. Both EFV and NVP also
have the ability to induce the enzymes that are responsible
for their own metabolism and may increase the clearance of
co-administered drugs that share these metabolic pathways [24].
The newest NNRTI, etravirine (ETV), is similarly CYP
metabolized and subject to interactions with rifamycins.
Table 1 illustrates the impact of RIF and RFB on NNRTI
and PI AUC, with accompanying recommendations for
dose modification.
2.2.1 Efavirenz
EFV has been widely studied and in clinical use
for > 10 years [39]. EFV is principally metabolized by
CYP2B6, with women and individuals with the 516G >
T single nucleotide polymorphism appearing to have higher
drug exposure [39,40].
When combined with RIF, there appears to be a 22 -- 25%
reduction in peak and trough EFV concentrations in cauca-
sian populations. Accordingly, recommendations to increase
the dose of EFV from 600 to 800 mg in patients
weighing > 60 kg have been issued [41,42]. This reduction in
concentration is less evident in Black [43,44] and Asian [45-47]
adult patients, although high inter-patient variability in
concentrations has been reported. In these populations, clini-
cians have been able to successfully co-administer standard
600 mg EFV dosing with RIF and EFV dose augmentation
appears not to be necessary. If resources permit, considera-
tion should be given for therapeutic drug monitoring of
EFV and pre-emptive 516G > T genotyping, as there appears
to be variability in drug handling amongst different
populations [48].
2.2.2 Nevirapine
NVP is generally used during pregnancy or when EFV is
contraindicated. NVP is thought to be associated with higher
risk for symptomatic hepatic adverse events in ART-
naive patients with pre-ART CD4 cell counts > 400 cells/
mm3 if male and CD4 > 250 cell/mm3 if female [49]; however,
in a ‘Rapid Advice’ communication in November 2009 by the
WHO [50], these added risks were not confirmed.
NVP is metabolized primarily by CYP3A4 and RIF is a
potent inducer of this isozyme. Co-administration of the
two agents should be avoided due to reports of a 20 -- 58%
reduction in NVP concentration [49,51]. Options to increase
the dose of NVP from 200 mg twice daily to 300 mg twice
daily to counteract the RIF induction effect have been
approached cautiously in studies with small numbers of
patients [52]. This dose amendment is not currently recom-
mended due to higher rates of NVP hypersensitivity [53]. An
important recommendation by the WHO is that in the pres-
ence of RIF or when switching from EFV to back to NVP no
lead-in dose is required [54]. This recommendation is sup-
ported by two studies which show that the omission of the
NVP lead-in dose is safe [55] and ensures therapeutic drugs
concentration are reached [56]. NVP has been reported in a
cohort study to be less affected by the NVP--RIF interaction
in its ability to suppress viral load when combined with TB
treatment if NVP treatment is established prior to TB treat-
ment initiation [57]. However, the majority of studies includ-
ing the N2R randomized controlled trial have shown that
EFV is more effective, has fewer adverse events, is the more
durable and the preferred of the two NNRTIs when
combined with TB treatment [45,57-59].
2.2.3 Delavirdine
Delavirdine (DLV) has a lower efficacy than other NNRTIs
and needs to be administered more frequently. These factors
have led the US DHHS (Department of Health and Human
Initiating antiretrovirals during tuberculosis treatment
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Services) not to recommend its use as part of first-line
treatment. Cross-resistance in the NNRTI class, as well as
DLV’s potential for drug interactions (potent inhibitor of
CYP3A4), makes the place of this agent in second-line and
salvage therapy uncertain [49].
2.2.4 Etravirine
This new NNRTI is not widely available in high prevalence
HIV--TB areas. There is little clinical experience or published
data on the combination of ETV with TB treatment. How-
ever, based on its pharmacokinetic profile, ETV is a substrate
of CYP3A4, CYP2C9, CYP2C19, an inducer of CYP3A and
an inhibitor of CYP2C9, CYP2C19 and p-glycoprotein [60].
Co-administration of drugs that are substrates at or induce
these pathways may have unknown effects on the therapeutic
concentrations of ETV and vice versa [60].
2.3 Drug interactions between RIF/RFB and
boosted PIs
PIs are associated with many clinically relevant drug
interactions [21]. PIs are mostly substrates of CYP3A4 and
P-glycoprotein, with the exception of nelfinavir (NFV) which
is metabolized by CYP2C19 [20]. Ritonavir (RTV) also has
the ability to potently inhibit CP3A4 and P-glycoprotein efflux
pumps and this property has been used to therapeutic advantage
in combination with other PIs. These combinations of low-
dose RTV and PIs, commonly referred to as boosted PIs,
show enhanced activity (plasma concentration) and increased
likelihood of viral suppression [61]. Co-administering unboosted
PIs with RIF has been shown to result in > 90% reduction in PI
trough concentrations [27,33]. PI AUC reduction due to RFB is
15 -- 45% [62]. Boosting with low-dose RTV may not be suffi-
cient to overcome the RIF effect [63-65] and suggestions to add
high doses of RTV (super-boosted PIs) have been made [64].
Safety concerns (hepatic adverse events) and poor tolerance
curtail these treatment options [66], making individualized
treatment with careful laboratory monitoring essential.
2.3.1 Atazanavir
The co-administration of RIF and boosted atazanavir (ATV)
is contraindicated due to a combination of poor hepatic and
gastrointestinal tolerability [67] as well as sub-therapeutic
ATV plasma concentrations [68,69].
2.3.2 Darunavir
Darunavir was FDA approved in 2006 but to date there are
no published studies available on co-administration with
RIF. This is not surprising as the manufacturer has contrain-
dicated its use based on the predicted effects of lowered ther-
apeutic concentration and efficacy when combined with RIF,
as is the current clinical experience with other PIs [70].
2.3.3 Amprenavir/fosamprenavir (prodrug)
Co-administration of RIF and amprenavir (APV) or
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healthy volunteers reported that RIF induced an 82% reduc-
tion in the AUC of APV and that APV caused a significant
decrease in clearance of RFB [72].
2.3.4 Indinavir
The AUC of indinavir (IDV) is reduced 89% by RIF and this
combination should not be co-administered. RFB clearance is
reduced in the presence of IDV and IDV concentrations are
reduced by 32%. An increase in IDV dose to 1000 mg every
8 h with RFB is recommended [61,71].
2.3.5 Nelfinavir
Plasma concentrations of NFV are reduced by 82% by RIF
and the two agents should not be co-administered. RFB has
insignificant effect on NFV concentration, but RFB AUC
increases 207%, requiring RFB dose adjustment [71].
2.3.6 Lopinavir
Lopinavir (LPV) is co-formulated with RTV (referred to as
LPV/r) and is widely accessible in high TB-prevalence coun-
tries. Clinical data on dose modification when combined
with RIF are limited and in some instances concerning.
A study in 40 healthy volunteers had to be prematurely termi-
nated due to high rates of grade 4 serum transaminase eleva-
tion when LPV/r was super-boosted with a higher dose of
RTV or when double dose LPV/r was used to counteract
the RIF effect [73]. In a retrospective analysis of observational
data, 34 patients treated concomitantly with LPV/r and RIF
were studied. Increased dosing of LPV/r was used in only
15% of patients and 40% of them had to prematurely stop
the drug due to adverse events (nausea, vomiting, liver enzyme
elevations). In the 85% of patients who were maintained on
standard doses, 67% had a sub-therapeutic LPV plasma con-
centration and 38% had a detectable viral load [74]. The US
DHHS [49] and Centers for Disease Control [71], therefore,
do not recommend the combination with RIF. RFB is
recommended as a possible substitute for RIF. However, in
clinical practice, particularly in developing countries where
the RIF + LPV/r combination is often unavoidable and RFB
is unavailable, RTV super-boosting or double strength LPV/
r is prescribed [33]. The WHO recommends RTV super-
boosting (LPV 400 mg + RTV 400 mg twice daily) or double
dose (LPV 800 + RTV 200 mg twice daily) with liver enzyme
functioning and viral response monitoring [54]. These doses
was tested in 32 healthy subjects and found to be of moderate
tolerability with a 31% discontinuation rate in the higher-
dose LPV/r arms. The 800/200 mg dose exhibited lower rates
of liver function test elevation and half as many discontinua-
tions. [64]. Additionally, in a small pharmacokinetic study
conducted in 30 South African children, LPV/r pharmacoki-
netics was compared in 15 children taking LPV/r in a 1:1 ratio
(super-boosted) with RIF to 15 children taking LPV/r in the
standard 4:1 ratio without RIF. The investigators found that
LPV oral clearance was 30% lower in the non-TB-infected
children compared to the super-boosted LPV clearance
and encouragingly the predicted Cmin was above the
recommended minimum during TB treatment [75].
Concomitant RFB and LPV/r use in healthy volunteers
demonstrated a > 300% increase in RFB AUC and no effect
on LPV/r AUC with a resultant RFB dose reduction recom-
mendation [71]. However, RFB 150 mg three times weekly
in combination with LPV/r resulted in inadequate RFB levels
and led to acquired rifamycin resistance in patients with HIV-
associated TB [76,77]. Current dosing recommendations
require revision. Empiric evidence to guide safe and effective
dose adjustment of LPV/r and RIF and RFB is urgently
needed as treatment programs mature in developing countries
and more patients move onto PI-based regimens.
2.3.7 Ritonavir
RTV is generally administered in conjunction with other
PIs where its ability to inhibit CYP3A4 is exploited for
therapeutic effect [61].
2.3.8 Saquinavir
Due to reports of serious hepatotoxicity in healthy volunteers,
the combination of RIF and boosted saquinavir (SQV) is best
avoided if possible [64,78]. RFB may be co-administered with
SQV + RTV [71].
2.3.9 Tipranavir
Tipranavir (TPV) is mainly metabolized by CYP3A4 and has
been boosted with low dose RTV to enhance its plasma expo-
sure. No clinical experience is available with these combina-
tions in TB--HIV infected individuals. However, RFB may
be safe to use with dose adjustment and a predictable RIF
interaction may be inferred from its metabolic pathway until
substantive evidence becomes available [79].
2.4 CCR5 co-receptor antagonist
2.4.1 Maraviroc
There is very limited published clinical experience with mara-
viroc (MVC) and the rifamycins. MVC is metabolized by
CP3A4 and is, therefore, subject to interactions with inhibi-
tors and inducers of that isoenzyme such as the PIs (except
for TPV), NVP, EFV and RIF [80,81]. TPV/r does not appear
to affect the steady-state pharmacokinetics of MVC [82]. This
agent is limited to use in treatment-experienced patients who
are not infected with CXCR4-tropic virus. Dose reduction is
advocated if MVC is administered with potent inhibitors and
dose increase if administered with potent inducers of




Raltegravir (RGR) is not a substrate of CYP enzymes and is
metabolized via the UGT1A1 glucuronidation pathway [83].
RIF is a strong inducer of UGT1A1 and although there is
limited clinical experience with RGR, it is recommended
Gengiah, Gray, Naidoo & Karim

















































































that RIF be used with caution with RGR as trough concentra-
tions of the ARV may decrease by 40 -- 61%. A recent update
to the package insert recommended a dose increase of RGR to
800 mg twice daily if co-administered with RIF [71,83].
2.6 Other reverse transcriptase inhibitors and
rifamycins
The NRTIs do not appear to have any significant known drug
interactions with the rifamycins with the exception of the lim-
ited published data with ZDV [84]. RIF may increase glucuro-
nidation of ZDV, thereby, decreasing ZDV AUC by 47%
[85]. In practice, this combination is not contraindicated so
long as there is adequate laboratory monitoring of viral load.
Tenofovir disporoxil fumarate (TDF), a nucleotide reverse
transcriptase inhibitor, is now increasingly available in
resource-constrained settings. TDF is advocated for use in
HIV, HIV/hepatitis B (HBV) and TB--HIV co-infected
patients [86]. TDF (not a substrate of CYP) is eliminated by a
combination of glomerular filtration and active tubular secretion
and in a study of 24 healthy volunteers receiving both TDF and
RIF, no changes in the pharmacokinetic parameters of either
drug were noted [87]. The nephrotoxic potential of TDF in
long-term treatment has been reviewed [88]. Increased risk for
nephrotoxicity exists with TB co-treatment when other agents
with nephrotoxic potential such as aminoglycosides are utilized
for TB re-treatment or MDR/XDR TB treatment. Extra
vigilance in renal function monitoring is indicated.
3. Interactions between ARVs and anti-TB
drugs used in multidrug- and extensively
drug resistant TB
MDRTB is defined as TBwhich is resistant to both RIF and iso-
niazid and accounts for 5% of the global TB burden [89]. XDR
TB is defined as MDR TB that is, in addition, resistant to a flu-
oroquinolone and at least one second-line injectable agent [90].
MDR TB and HIV co-infected patients have an exceedingly
high mortality rate [4,91,92]. There is potential for ARV and TB
drug interactions in the MDR and XDR TB treatment setting
given the multiple drug classes exhibiting differing pharmacoki-
netic profiles (aminoglycosides, fluoroquinolones, thioamides,
cycloserine, para-aminosalicylic acid, clofazimine, macrolides,
linezolid) that will need to be safely used in combination [90].
More evidence-based, pharmacokinetic and clinical data are
required when these drug classes are combined to be able to
guide the field on dosing. This topic is beyond of the scope of
this review but mentioned due to its importance when
combining ART and drug resistant TB drugs.
4. Drug toxicities and adherence challenges
when combining TB--HIV treatment
Barriers to TB--HIV treatment integration include fears about
drug toxicities attributed to individual drug agents being
enhanced when treatments are combined. In addition, the
potential for a detrimental impact on adherence to treatment
because of the high pill burden associated with HIV, TB and
other opportunistic infection drugs has historically been a
cause for concern.
4.1 Additive and overlapping toxicities
HIV and TB drugs are independently associated with signifi-
cant toxicities. When combined, drug-related toxicities may
be additive or might overlap, resulting in increased potential
for morbidity, premature disruption of treatment/s and in
some cases life-threatening adverse effects.
The potential for adverse events due to the interaction
between ART and anti-TB drugs that have similar toxicity
profile is due to shared pharmaco-metabolic pathways, the
most common manifestation of which is hepatotoxicity [6].
Hepatotoxicity can occur in 5 -- 10% of patients in the first
year following ART initiation, and this risk is enhanced if
the patient is hepatitis C and/or B co-infected. [93]. Reports
indicate that HIV infected patients may be predisposed to
higher rates of drug-related adverse events [94], including
severe liver toxicity, when on anti-TB treatment [95,96]. High
baseline bilirubin, low CD4 cell counts between 50 and
100 cell/m3 and the use of fluconazole prescribed in the first
week of TB treatment have been shown to be significant risk
factors for liver toxicity [97]. A study of the risk of elevated
grade 3 or 4 hepatic enzymes during RTV boosted PI use in
1161 patients revealed the following incidence: NFV, 11%;
LPV/r (RTV = 200 mg/day), 9%; IDV, 13%; IDV + RTV
(RTV = 200 -- 400 mg/day), 12.8%; and SQV + RTV
(RTV = 800 mg/day), 17.2% [98]. In a South African study
of 868 HIV-positive patients, of whom 25% were receiving
concomitant TB treatment during ART, episodes of severe
hepatotoxicity were reported at a rate of 7.7/100 person-years,
with an 8.5-, 3- and 1.9-fold increased risk if on TB treat-
ment, HBsAg positive and possessing a nadir CD4 cells
count < 100 cells/mm3, respectively [99]. Of further impor-
tance in this study, the proportion of patients with severe hep-
atotoxicity on ART (4.6%) was similar to the proportion with
liver enzyme elevations > 5 times the upper limit of normal
before starting ART (4%) [99]. Tolerance of the NNRTIs
was assessed in a cohort analysis of 2035 individuals who
started ART with EFV (1074 with concurrent TB) and
1935 with NVP (209 with concurrent TB). The risk of
toxicity-mediated NNRTI substitution in patients on concur-
rent TB treatment was increased in patients on NVP (adjusted
hazard ratio (HR) 1.5; 95% CI 0.8 -- 2.8), but this estimate
did not reach statistical significance. In patients without
concurrent TB, those on NVP were more likely to have their
therapy substituted by 6 months due to toxicity compared
with those on EFV (cumulative proportion: 4.9%; 95% CI
3.9 -- 6.1% (NVP) vs 1.4%; 95% CI 0.8 -- 2.4%
(EFV)) [57]. In the SAPiT randomized clinical trial conducted
in 642 HIV--TB co-infected South African patients who were
randomly assigned to ART at two time points during and
after TB treatment completion, 140 grade 3 or 4 adverse
Initiating antiretrovirals during tuberculosis treatment

















































































events that were not regarded as immune reconstitution
occurred in the TB--HIV co-treated group (30/100 person-
years) and 71 in the TB treatment only group (32/100
person-years) (p = 0.69) [14].
With TB treatment alone, the reported incidence of drug-
induced hepatotoxicity ranges from 2 to 28%, depending on
the presence of risk factors such as advanced age, female gen-
der, low acetylator status, malnutrition, presence of HIV
infection and pre-existing liver disease and the exact mecha-
nism is not clearly understood [26]. In a Canadian study of
serious side effects (rash, hepatitis and gastrointestinal) from
first-line TB treatment in 430 patients, the incidence of all
major adverse events was 1.48/100 person-months, (95% CI
1.31 -- 1.61) for pyrazinamide, 0.49 (95% CI 0.42 -- 0.55)
for isoniazid, 0.43 (95% CI 0.37 -- 0.49) for RIF and
0.07 (95% CI 0.04 -- 0.10) for ethambutol [96]. In this study,
the adjusted HR for major adverse events was 3.8 (95% CI
1.05 -- 13.4) in HIV-positive patients [96].
Peripheral neuropathy is also an important predictor of
treatment-limiting toxicity in TB--HIV co-treatment. In a
South African study of 7066 HIV patients initiated on stavu-
dine as part of the national first-line ART regimen at the time,
those on concurrent TB treatment were more likely to require
stavudine substitution in the first 2 months of ART treatment
(adjusted HR 6.6; 95% CI 30 -- 14.37) [100]. Almost half
(43%) of the 842 single-stavudine substitutions in this analy-
sis were attributed to peripheral neuropathy and these patients
were more likely to be on TB treatment at ART initiation or
during follow-up (relative risk 1.53, 95% CI 1.33 -- 1.75).
Isoniazid is the TB drug most likely to be associated with
peripheral neuropathy [101] as are the ARVs, stavudine [102]
and didanosine [103].
Other important shared adverse events in TB--HIV
co-treatment incorporating the standard use of co-trimoxazole
are hypersensitivity reactions (NVP, abacavir, co-trimoxazole,
TB drugs), gastrointestinal disorders (didanosine, ZDV, PIs,
TB drugs), anemia (ZDV) and CNS manifestations (EFV,
isoniazid), which in some cases may necessitate stopping the
causative drugs, even though the preference is to manage the
symptoms and maintain patients on the most efficacious
combination regimens available [7,90,104].
It is recommended that all HIV-positive patients receiving
TB and ART simultaneously have baseline hepatitis B [99]
and hepatitis C screening, liver function test (AST, bilirubin,
ALT) and full blood count with platelets, prior to initiation of
either treatment. Routine safety checks of the liver and
hematological parameters as well as frequent clinical symptom
monitoring are recommended to ensure that hepatic
flares or worsening laboratory parameters (which may be
asymptomatic) are detected early. In a typical TB--HIV
co-treatment scenario, several activities may occur in close
succession, and optimal drug sequencing needs to be estab-
lished to best manage the adverse drug reactions that may
occur in order to improve tolerability to necessary drug
regimens. A patient’s inability to tolerate the treatment will
curtail therapeutic options even though the limited treatment
available may still be effective.
4.2 Adherence challenges in combination treatment
Optimal adherence to both long-term chronic ART and shorter
course anti-TB treatment is critical. There is an established
direct relationship among poor adherence, treatment failure
and the development of resistance [105], making adherence an
important public health safety concern. Adherence to TB treat-
ment is complex and involves many facets and structural bar-
riers that need to be identified and overcome [106]. Factors
that may predispose to less than optimal adherence include
high pill burden, poor drug tolerability [107], alcohol consump-
tion and having reached the continuous phase of TB treat-
ment [108]. Predictors of non-adherence are useful to guide
caregivers. In high prevalence settings, the challenges are even
more complex, encompassing economic, institutional, political
and cultural factors [109]. Settings that provide comprehensive,
multidisciplinary care such as adherence counseling, HIV,
TB, STI treatment and provision of all chronic treatment and
concomitant medication at a single facility may be a step in
the right direction to enhance adherence support.
5. IRIS associated with TB and HIV treatment
IRIS is a frequent early complication in the management of
TB--HIV co-infected patients initiating ART and is a result
of the recovering immune system recognizing previously
undetected antigens [110]. IRIS may present as unmasking of
pre-existing untreated opportunistic infections (mycobacteria,
herpes virus, cryptococcal meningitis) or the paradoxical clin-
ical deterioration of appropriately treated opportunistic infec-
tions such as pulmonary TB (TB IRIS), usually shortly after
ART initiation [111].
Patients develop clinical and radiographic manifestations of
IRIS such as fever, worsening chest radiograph, cervical aden-
opathy and pleural effusion, typically developing 2 -- 4 weeks
after starting ART [112-114]. However, delaying ART until the
continuation phase of TB treatment (2 months) does not pre-
vent the occurrence of TB IRIS [115]. Determination of TB
IRIS is challenging as there is no diagnostic test and reliance
is on pre-determined clinical case definitions, clinical and
laboratory data [111].
In a retrospective South African cohort study of
160 patients initiating ART whilst on TB treatment, IRIS
was diagnosed in 12% (n = 19) of patients where 12/19 started
ART within 2 months of TB diagnosis [116]. Low CD4 count
and short interval between TB and ART initiation were pre-
dictive of IRIS occurrence. The results of the SAPiT trial
were similar, with IRIS being diagnosed in 53/429 (12.4%,
95% CI 9.5 -- 15.9) and 8/213 (3.8%, 95% CI 1.8 -- 7.5)
patients in the TB--HIV and TB-only treatment arms,
respectively [14].
Mortality rates from TB IRIS have been reported in the
literature and in most instances are low [113,116,117]. The results
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of a pooled meta-analysis estimate that mortality from TB-
associated IRIS was ~ 3.2%, whereas mortality from all types
of IRIS was 4.5% [118]. However, TB IRIS is associated with
higher rates of morbidity and often requires hospitalization,
with Black race, low baseline CD4 count, extra-pulmonary
TB and a short time interval between TB treatment and
ART initiation being the most predictive of its occur-
rence [117,119]. In some settings, a greater rate of increase in
CD4 count from baseline to 6 months offers additional
predictive value [114,120].
In the clinical management of IRIS, combination ART has
been continued and management has been supportive and
symptomatic [104]. In a recently published randomized con-
trolled trial, the use of prednisone as a 4 week course
(1.5 mg/kg/day for 2 weeks then 0.75 mg/kg/day for 2 weeks)
in suspected TB IRIS following ART and TB co-treatment
reduced morbidity and the need for hospitalization [121].
6. Mortality from HIV progression and TB
co-infection
The positive impact (reduction in AIDS progression and death)
of combining ART and acute opportunistic infection treatment
was demonstrated in the A5164 study [122]. There are also a
growing number of observational studies from developing
countries demonstrating reduction of mortality rates specifi-
cally in TB--HIV co-infected patients when HAART was intro-
duced early during TB treatment [9,11,123-127]. The retrospective
cohort study by Velasco et al. [125] showed that patients starting
ART within 2 months of TB treatment start had a significantly
improved survival benefit (HR 0.38; 95% CI 0.20 -- 0.72)
compared to those who did not. Additionally, the effect of
delaying ART in 573 children by 15, 30 or 60 days after TB
treatment start revealed that delays of 2 or more months are
associated with less than optimal virological response and
increased mortality [128].
These data are consistent with the interim results of the
SAPiT randomized clinical trial [14]. The SAPiT trial was
conducted in 642 ambulant HIV--TB co-infected South
African patients, who were randomly assigned to ART at
two time points during TB treatment (with 4 weeks of TB
treatment start, within 4 weeks after 8 weeks of TB treat-
ment was completed) and after completion of TB treatment.
The integrated therapy groups were associated with a mor-
tality rate of 5.4 deaths/100 person-years compared to
12.1/100 person-years in the sequential group (HR 0.44;
95% CI 0.25 -- 0.79), which translates to a relative risk
reduction of 56% when ART and TB treatment are
combined [14].
In addition to the SAPiT trial results, the findings of the
CAMELIA study, the second RCT in this arena, were
presented at the 18th International AIDS conference in
Vienna, 2010 [129]. This prospective clinical trial was
conducted in 661 Cambodian patients, who were randomized
to early (2 weeks post-TB treatment start) versus late
(8 weeks post-TB treatment start) ART initiation and were
characterized at baseline as being severely immune-
compromised. In this study, the median CD4 cell count was
25 cells/m3. The mortality rate in the early arm was
8.3 (95% CI 6.4 -- 10.7) versus 13.8 (95% CI 11.2 -- 16.9)
in the late arm. The study demonstrated that the initiation
of ART in the first 2 weeks of TB treatment significantly
reduces mortality in the severely immune-compromised.
7. Conclusions
There is now more robust evidence to guide the clinical man-
agement of TB--HIV co-infected patients. Rational combina-
tion and sequencing of TB--HIV treatment, understanding
the potential for significant pharmacokinetic drug interactions
between rifamycins and ARVs, detecting drug-related hepato-
toxicity and neuropathies associated with drugs used for each
condition and managing TB IRIS after initiation of ART are
key priority areas for successful treatment integration. Under-
standing these complexities and how to manage them
diminishes the previous barriers to safe treatment integration.
Integrating ART with TB treatment is critical to improve
survival outcomes. Indications from current evidence are
that early integration of ART and TB treatment, as early as
2 weeks but within 2 months after TB drug initiation, is
safe and effective. Combining ART and TB drugs that are
compatible, have manageable and predictable drug interaction
profiles and good tolerability are essential for successful treat-
ment integration. In this regard, the NNRTIs, EFV in partic-
ular, are shown to be better able to withstand the effects of the
rifamycins than the PIs. Dose adjustment of ART should be
individualized according to recommendations in Table 1 in
order to maintain therapeutic concentrations with appropriate
clinical monitoring where necessary. Based on current evi-
dence, individualized laboratory monitoring and attention to
clinical presentation would be most beneficial in at least the
first 2 months of combined TB--HIV treatment. The use of
therapeutic drug monitoring and pharmacogenetic testing if
indicated may be a useful adjunct in settings where feasible
and available.
8. Expert opinion
8.1 Key findings of research
It is clear that improved survival of TB--HIV co-infected
patients is dependent on the early integration of treatment.
Failure to integrate ART and TB treatment due to fear of
potential drug--drug interactions or IRIS will result in excess
mortality. The drug management of HIV and TB is entering
a new era of confidence due to the emergence of substantive
evidence on which to base policies and practice. Overlapping
toxicities are now better understood and, although not always
predictable, are found not to be treatment limiting. Data and
experience with individual agents are now available for
decisions to be made by caregivers as well as policymakers.
Initiating antiretrovirals during tuberculosis treatment

















































































8.2 Limitations of available research
Much of the available data on drug interactions are from
healthy volunteers or small clinical studies and there is a
paucity of robust drug interactions studies in patients
who have the diseases in question. The findings of such
studies may have poor external validity when applied to
HIV--TB co-infected patients [130]. There is also a general
lack of information and published clinical experience on
drugs used in MDR and XDR TB and their potential
interactions with ARVs. Although pharmacogenetic testing
for CYP polymorphisms and therapeutic drug monitoring
is advocated with certain ART and TB drugs, the evidence
for a clear benefit that justifies resource allocation is not
yet available.
The focus of this safety review is on non-pregnant adult
patients but TB co-infection in HIV-positive pregnant
women in sub-Saharan African is a major non-obstetric cause
of mortality [131]. Therefore, efforts need to be focused on this
population. Additionally, children and young adolescent
women undergoing physical development are also vulnerable
to TB--HIV co-infection. Safe, rational and well-researched
drug choices need to be made available with the appropriate
pharmacokinetic and clinical data to guide optimal decision
making in these patient groups.
8.3 Future research priorities
Pressing research priorities include assessing the safety and
efficacy of double dose and super-boosted PIs with RIF-
based TB regimens and assessing the hepatic safety of omit-
ting the lowered lead-in dose of NVP, which may in part
have contributed to the higher proportion of virological
failure seen with NVP compared to EFV when combined
with TB treatment. Pharmacokinetic studies in TB--HIV
co-infected children and pregnant women are of great impor-
tance as drug handling in these groups differ from the stan-
dard 70 kg adult in which most dosing is classically derived.
These data are critically needed in resource-poor high
TB--HIV prevalence regions.
Opportunities for research that enhances the understanding
of the mechanisms and extent of anticipated drug interactions
with MDR and XDR TB drugs and ART must be acted
upon. The incidence of MDR/XDR TB is on the increase
and fatalities will be excessive if strategies to co-treat are not
rapidly devised. Additionally, testing multiple combinations
of ARVs with TB treatment in those co-infected is essential
to provide more treatment options and flexibility. More
potent drugs that reduce pill burden and shorten the duration
of TB treatment are important to develop and continued
efforts need to be made to research new compounds for
both TB and HIV, as the current armamentarium is still
very limited and in constant danger of being exhausted [132].
As the HIV epidemic matures and treatment becomes
available in developing countries over a sustained period, the
need for second-line ARV drugs that are compatible with
TB drugs will become critical. Future work needs to be
more attentive to these needs. Several newer classes of ARVs
and newer drugs in the older classes have now become avail-
able. Well-designed drug interaction studies with rationally
sequenced drugs that take into account the time to enzyme
induction need to be conducted to ascertain their utility in
co-infection, for example, increasing RTG dose to 800 mg
or MVC to 600 mg when combined with RIF. There is lim-
ited experience with RFB use in HIV-positive patients and
greater access should be available in resource poor settings in
single drug and fixed dose combinations to test the efficacy
of RFB as an alternate to RIF. Another RIF replacement
that shows promise to possibly shorten the duration of TB
treatment is moxifloxacin [133] and future research results are
eagerly awaited. The anti-TB drugs TMC 207 and linezolid
are also in Phase III and II testing and this testing needs
to incorporate potential drug interactions with other TB
treatment as well as ART.
Given the increased risk of morbidity and mortality associ-
ated with TB--HIV co-infection and the complexities of
integrating treatment, strategies to prevent TB acquisition in
the first place warrant further operational research in high
TB prevalence settings. Granich et al. outline the ‘Three Is
for HIV--TB’ which are isoniazid preventative therapy,
intensified case finding and infection control for TB [134].
Finally, operational studies on integrated comprehensive
care from screening to treatment are now essential to inform
best practice and to impact positively on adherence, TB and
HIV case finding as well as TB and HIV prevention. Oppor-
tunities also exist through the PEPfAR- and GFATM-funded
ART programmes for enhanced pharmacovigilance and
assimilation of these data to better inform practice.
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